Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Vandetanib is a multi-targeted receptor tyrosine kinase inhibitor that is in clinical development for the treatment of solid tumours. This preclinical study examined the inhibition of two key signalling pathways (VEGFR-2, EGFR) at drug concentrations similar to those achieved in the clinic, and thei...

书目详细资料
Main Authors:	Brave, SR, Odedra, R, James, N, Smith, N, Marshall, G, Acheson, K, Baker, D, Howard, Z, Jackson, L, Ratcliffe, K, Wainwright, A, Lovick, S, Hickinson, D, Wilkinson, R, Barry, S, Speake, G, Ryan, A
格式:	Journal article
语言:	English
出版:	2011

相似书籍

In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival
由: Brave, SR, et al.
出版: (2007)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
由: Pacey, S, et al.
出版: (2016)

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice.
由: Alferez, D, et al.
出版: (2008)

Biophysical and computational characterization of vandetanib–lysozyme interaction
由: Kabir, Md Zahirul, et al.
出版: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
由: Abdul Qadir, MPhil, et al.
出版: (2023-10-01)

Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
由: Alferez, D, et al.
出版: (2010)

Inhibitory effect of luteolin on the metabolism of vandetanib in vivo and in vitro
由: Yuxin Shen, et al.
出版: (2025-03-01)

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
由: Smith, N, et al.
出版: (2010)

Design and Synthesis of New Dihydropyrimidine Derivatives with a Cytotoxic Effect as Dual EGFR/VEGFR‑2 Inhibitors
由: Lamya H. Al-Wahaibi, et al.
出版: (2024-08-01)

Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma
由: Xiaoyue Zeng, et al.
出版: (2024-05-01)

Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma
由: Maho Onda, et al.
出版: (2023-08-01)

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
由: Nichole E. M. Kaufman, et al.
出版: (2021-02-01)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
由: Chike Osude, et al.
出版: (2022-05-01)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib
由: Kyoichi Kaira, et al.
出版: (2023-10-01)

Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors
由: Hesti Lina Wiraswati, et al.
出版: (2023-07-01)

Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
由: Choi, S, et al.
出版: (2008)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
由: А. М. Mudunov, et al.
出版: (2019-10-01)

VEGFA, VEGFR1, VEGFR2 serum and cerebrospinal fluid concentration in patients with acute leukemia
由: E. I. Zakharko, et al.
出版: (2024-04-01)

Sesamol inhibits LPS induced angiogenesis via downregulating VEGFA/VEGFR2 signalling both in vitro and in vivo
由: Aparna N S, et al.
出版: (2023-12-01)

Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.
由: Alferez, D, et al.
出版: (2012)

New series of 4,6-diaryl pyrimidines: facile synthesis and antiproliferative activity as dual EGFR/VEGFR-2 inhibitors
由: Yaser A. Mostafa, et al.
出版: (2024-11-01)

Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
由: Siemann, D, et al.
出版: (2009)

Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
由: Wachsberger, P, et al.
出版: (2009)

Retraction: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
出版: (2024-01-01)

Association of VEGFR1, VEGFR2 and VEGFR3 polymorphisms with esophageal cancer risk: a case–control study
由: Sukhpreet Kaur Walia, et al.
出版: (2024-08-01)

Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through Deep Learning for the treatment of Cervical Cancer
由: Anuraj Nayarisseri, et al.
出版: (2024-06-01)

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
由: Heymach, J, et al.
出版: (2008)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
由: Ai Matsui, et al.
出版: (2022-01-01)

Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
由: Abdulmalik S. Altamimi, et al.
出版: (2021-05-01)

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt
由: Gupta, A, et al.
出版: (2016)

The importance of including both sexes in preclinical sleep studies and analyses
由: Grant S. Mannino, et al.
出版: (2024-10-01)

Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models
由: Hongyu Kuang, et al.
出版: (2024-10-01)

Critical Roles of VEGFR1, VEGFR2, VEGFR3, BAX, and BCL-2 in the Pathogenesis of Varicose Veins: Unveiling Molecular Mechanisms
由: Mehdi Abedinzadeh, et al.
出版: (2025-03-01)

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
由: Cesca, M, et al.
出版: (2009)

Vandetanib alters the tumoricidal capacity of human breast cancer stem cells via inhibiting vasculogenic capacity
由: Sanya Haiaty, et al.
出版: (2023-09-01)

Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells.
由: Sarvenaz Sarabipour, et al.
出版: (2024-02-01)

Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway
由: Yuanfang Tang, et al.
出版: (2022-12-01)

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
由: Jr, W, et al.
出版: (2012)

Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors
由: Mohamed A. Mahmoud, et al.
出版: (2024-12-01)

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
由: Hanrahan, E, et al.
出版: (2010)